FFO
TVRD

Fortitude Family Office’s Tvardi Therapeutics TVRD Stock Holding History

Fortitude Family Office’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-127
Closed -$546 – 2116
2025
Q4 		$546 Buy
+127
New +$1.14K ﹤0.01% 1677

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Fortitude Family Office's TVRD Position: Q1 2026 in Review

Fortitude Family Office sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 127 shares — an estimated $546 sold.

Fortitude Family Office first reported a position in TVRD in Q4 2025 and held it in 1 quarter. The position peaked at $546 in Q4 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Fortitude Family Office reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fortitude Family Office sold 127 Tvardi Therapeutics shares in Q1 2026, an estimated $546.
  • Fortitude Family Office first reported a position in Tvardi Therapeutics in Q4 2025 and held it in 1 quarter.
  • Fortitude Family Office's Tvardi Therapeutics position peaked at $546 in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.